RESUMEN
Levamisole (Lms) is an anthelminthic drug with immunomodulatory activity. Chagas disease (CD) is caused by Trypanosoma cruzi and there is very low access to the drugs available, benznidazole (Bz) and nifurtimox, both far from ideal. In a drug-repurposing strategy to test potential activity as antiparasitic and immunomodulatory agent for CD, Lms was assayed on acute T. cruzi murine infection, alone and in co-administration with Bz. During protocol standardization, 100 and 10 mpk of Bz given for five consecutive days resulted in parasitaemia suppression and 100% animal survival only with the highest dose. Flow cytometry showed that both optimal (100 mpk) and suboptimal (10 mpk) doses of Bz equally decreased the plasma levels of cytokines commonly elevated in this acute infection model. Lms alone (10-0.5 mpk) did not decrease parasitaemia nor mortality rates. Co-administration was investigated using the suboptimal dose of Bz and different doses of Lms. While Bz 10 mpk did not alter parasitaemia, the combo partially reduced it but only slightly promoted animal survival. This effect could be related to Th1-response modulation since interleukin-6 and interferon-γ were higher after treatment with the combo.
Asunto(s)
Enfermedad de Chagas/tratamiento farmacológico , Levamisol/farmacología , Nitroimidazoles/farmacología , Parasitemia/tratamiento farmacológico , Tripanocidas/farmacología , Trypanosoma cruzi/efectos de los fármacos , Animales , Quimioterapia Combinada , Femenino , Masculino , RatonesRESUMEN
O presente trabalho registra a presença de metaplasia cartilaginosa em rim de peixes "espada" (Trichiurus lepturus), capturadosno litoral de Niterói, RJ, O exame histopatológico revelou estruturás nodulares levemente basófilas circundadas por umafina faixa de tecido conjuntivo inflamatório.
